What Is The Symani Surgical System?
Symani is a robotic-assisted microsurgery system developed by Medical Microinstruments (MMI), a company with operations in Pisa, Italy and Wilmington, Massachusetts. It is designed to assist surgeons performing open soft-tissue microsurgery and super-microsurgery — procedures on structures such as small blood vessels, nerves, and lymphatic channels that are difficult to manipulate with the human hand alone.
The system uses two robotic arms with wristed instrument tips, controlled by a surgeon seated at a console. MMI states the instruments can replicate hand movement at a reduced scale while filtering out physiological hand tremor, which is the core technical claim behind the product.
Symani is positioned as distinct from larger multi-quadrant systems like Intuitive's da Vinci, which are built primarily for minimally invasive endoscopic procedures. Symani is used in open surgical fields for reconstructive and lymphatic microsurgery rather than through small incisions.
| Attribute | Symani Surgical System | Note |
|---|---|---|
| Maker | Medical Microinstruments (MMI) | Pisa, Italy / Wilmington, MA, US |
| Category | Robotic-assisted open microsurgery | Not an endoscopic minimally-invasive platform |
| US regulatory status | FDA de novo authorization, April 2024 | Per FDA and company statements |
| EU regulatory status | CE marked | Per company statements |
| Example use cases | Lymphatic-venous anastomosis, free-flap reconstruction, replantation | See procedures section below |
FDA And CE Regulatory Status
According to MMI and contemporaneous trade-press reporting, the FDA granted Symani de novo authorization in April 2024, covering use for soft-tissue manipulation to perform microsurgery. Reporting from that period described it as the first FDA authorization of its kind for a dedicated robotic microsurgery platform for reconstructive procedures.
In Europe, Symani carries CE marking, which permits its sale and clinical use across the EU under applicable medical device regulation. Regulatory clearance covers the device and its stated intended use; it is not a guarantee of outcomes for any individual procedure or patient, and clearance details can be updated by the FDA or notified bodies after this page was written.
This page summarizes publicly reported regulatory status as of publication. For the authoritative and current record, consult the FDA's own database and MMI's official regulatory communications rather than relying solely on secondary summaries — including this one.
What Procedures Symani Is Used For
Public reporting and MMI's own materials describe Symani being used in open soft-tissue procedures where extremely small structures need to be reconnected or repaired. Reported use cases include lymphatic-venous anastomosis (connecting small lymphatic vessels to nearby veins to help manage lymphedema), free-flap reconstruction after tumor resection, and traumatic replantation surgery.
Hospitals and surgical teams who have publicized Symani cases have cited applications including post-mastectomy breast cancer reconstruction and extremity reconstruction. One US hospital reported performing what was described as a fully robotic-assisted microsurgical procedure from incision to closure using the system.
This page does not evaluate clinical outcomes, success rates, or make efficacy claims. Anyone considering a Symani-assisted procedure should discuss risks, benefits, and alternatives with a treating surgeon and consult the primary clinical literature rather than marketing or news summaries.
Company Background And Funding
Medical Microinstruments was founded to commercialize wristed micro-instrument technology for open microsurgery. According to company announcements and trade press, MMI raised a Series C round reported at $110 million, led by Fidelity Management & Research Company with participation from earlier backers, following a Series B round reported at $87 million led by Deerfield Management in 2022.
Reported cumulative funding across MMI's rounds exceeds $200 million as of the most recent public disclosures available at the time of writing. These figures come from company and press announcements rather than audited public filings, since MMI is privately held.
For context on how Symani compares to the broader class of surgical and medical robotics, see our surgical robots overview and our da Vinci Surgical System review.
How Symani Differs From Other Surgical Robots
The most commonly cited comparison point is Intuitive Surgical's da Vinci platform, reviewed on this site in our da Vinci Surgical System review. da Vinci is built primarily for minimally invasive, port-based endoscopic surgery across specialties like urology and gynecology, with an installed base in the thousands of systems worldwide. Symani targets a narrower, open-field microsurgery niche — reconstructive and lymphatic work on structures smaller than what da Vinci's instrument scale is designed for.
CMR Surgical's Versius, covered in our CMR Versius review, is a modular soft-tissue system aimed at broader general and gynaecological surgery rather than microsurgery specifically. None of these systems are directly interchangeable; each is cleared for a distinct scope of procedures, and choice of platform is a clinical and institutional decision made by hospitals and surgeons, not a like-for-like consumer comparison.
Readers new to the category should start with our robotics in healthcare comparison, which explains how surgical, hospital-logistics, rehabilitation, and assistive medical robots differ before drilling into any single platform.
Bottom Line
The Symani Surgical System is a robotic-assisted microsurgery platform from Medical Microinstruments, FDA-authorized in April 2024 and CE marked in Europe, built for open soft-tissue procedures such as lymphatic-venous anastomosis and free-flap reconstruction that require sub-millimeter instrument control. It occupies a distinct niche from broader endoscopic systems like da Vinci or Versius. Any decision about a Symani-assisted procedure belongs to a patient and their treating surgical team.
Compare Symani to other surgical robotics platforms in our surgical robots overview and da Vinci Surgical System review, or start with our robotics in healthcare guide for the wider medical robot landscape.
FAQs
What is the Symani Surgical System?
Symani is a robotic-assisted microsurgery system from Medical Microinstruments (MMI) that gives surgeons wristed, tremor-filtered instrument control for open soft-tissue procedures such as lymphatic and reconstructive microsurgery.
Is the Symani Surgical System FDA approved?
Symani received FDA de novo authorization in April 2024 for soft-tissue manipulation to perform microsurgery, according to MMI and trade-press reporting. Verify current status directly with the FDA's device database, since clearance records can be updated.
What is Medical Microinstruments (MMI)?
Medical Microinstruments is a medical device company, with operations in Pisa, Italy and Wilmington, Massachusetts, that develops the Symani robotic microsurgery platform. It is privately held and has raised over $200 million in reported venture funding.
What procedures is Symani used for?
Publicly reported use cases include lymphatic-venous anastomosis for lymphedema, free-flap reconstruction after tumor removal, and traumatic replantation surgery. This is an informational summary, not a clinical recommendation — discuss specific procedures with a treating surgeon.
How is Symani different from the da Vinci surgical robot?
da Vinci is built mainly for minimally invasive, port-based endoscopic surgery across many specialties, while Symani targets open-field microsurgery on structures smaller than da Vinci's typical instrument scale, such as small lymphatic vessels. See our da Vinci Surgical System review for a full comparison.